Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010, which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.  

CONTACT:
James E. Fickenscher
Chief Financial Officer, Auxilium Pharmaceuticals, Inc.
+1-484-321-5900
jfickenscher@auxilium.com
or
William Q. Sargent Jr.
Vice-President, Investor Relations and Corporate Communications
+1-484-321-5900
wsargent@auxilium.com

AUXILIUM PHARMACEUTICALS, INC.

Condensed Consolidated Statement of Operations

(In thousands, except share and per share amounts)

(Unaudited)Three Months Ended March 31,20112010Net revenues

$
58,369$
45,480Operating expenses*:Cost of goods sold

11,2529,451Research and development

15,7548,479Selling, general and administrative

43,15936,103Total operating expenses

70,16554,033Loss from operations

(11,796)(8,553)Interest Income (expense), net

(50)(56)Net loss

$
(11,846)$
(8,609)Basic and diluted
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 According to a ... Growth, Trends & Forecasts (2015-2020), , published by Mordor Intelligence, ... billion by the end of 2020, with North ... more than 40% of the global market size. The Global ... CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announces the launch of their 2nd generation cell therapy POD® design. The 2nd ... but it also represents a new POD® design. , “G-CON first offered ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... June 11 MedNet Solutions, a global life sciences ... will unveil a variety of exciting new and enhanced ... Annual Meeting, June 22-24, 2009, in San Diego, CA. ... its market-leading electronic data capture/eClinical tool set to improve ...
... ... how Earned Value Management can improve control over clinical development costs, payments, and accruals ... , ... (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical ...
... (Nasdaq: MDVN ) today ... CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial ... Alzheimer,s disease. , , The international, double-blind, ... the enrollment target of 525 patients. More than 40 ...
Cached Biology Technology:MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting 2ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... vibrant insects, with colorations sometimes designed to deflect predators. ... defenses may be driven by enemies one-tenth their size. ... researchers have believed large predators like birds mainly influenced ... behavioral study to directly test the defense mechanism of ...
... be it heat or electricity, has to be used right ... its transportation can be rather complicated. Creating solar cells capable ... that is to say fuel, is therefore the future challenge ... are working on a catalyst that imitates and improves what ...
... amino acids in order to conduct electricity, according to a ... open-access journal of the American Society for Microbiology, on Tuesday, ... sulfurreducens uses these nanowires, called pili, to transport electrons ... of these wires can also be harnessed by humans for ...
Cached Biology News:UF study shows spiders, not birds, may drive evolution of some butterflies 2UF study shows spiders, not birds, may drive evolution of some butterflies 3Catalysts that produce 'green' fuel 2Biological wires carry electricity thanks to special amino acids 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: